“Holidays” for osteoporosis drugs: A case-based approach

• A “drug holiday” can be considered for patients at low fracture risk; • It is optimal after completion of five years of alendronate and three years of zoledronic acid or risedronate use; • The “drug holiday” strategy should not be implemented for denosumab, estrogen, SERMs or teriparatide....

Descripción completa

Detalles Bibliográficos
Autores principales: Anagnostis, Panagiotis, Paschou, Stavroula A., Kenanidis, Eustathios, Lambrinoudaki, Irene, Potoupnis, Michael, Tsiridis, Eleftherios, Goulis, Dimitrios G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6580330/
https://www.ncbi.nlm.nih.gov/pubmed/31431887
http://dx.doi.org/10.1016/j.crwh.2019.e00127
_version_ 1783428005120442368
author Anagnostis, Panagiotis
Paschou, Stavroula A.
Kenanidis, Eustathios
Lambrinoudaki, Irene
Potoupnis, Michael
Tsiridis, Eleftherios
Goulis, Dimitrios G.
author_facet Anagnostis, Panagiotis
Paschou, Stavroula A.
Kenanidis, Eustathios
Lambrinoudaki, Irene
Potoupnis, Michael
Tsiridis, Eleftherios
Goulis, Dimitrios G.
author_sort Anagnostis, Panagiotis
collection PubMed
description • A “drug holiday” can be considered for patients at low fracture risk; • It is optimal after completion of five years of alendronate and three years of zoledronic acid or risedronate use; • The “drug holiday” strategy should not be implemented for denosumab, estrogen, SERMs or teriparatide.
format Online
Article
Text
id pubmed-6580330
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-65803302019-08-20 “Holidays” for osteoporosis drugs: A case-based approach Anagnostis, Panagiotis Paschou, Stavroula A. Kenanidis, Eustathios Lambrinoudaki, Irene Potoupnis, Michael Tsiridis, Eleftherios Goulis, Dimitrios G. Case Rep Womens Health Article • A “drug holiday” can be considered for patients at low fracture risk; • It is optimal after completion of five years of alendronate and three years of zoledronic acid or risedronate use; • The “drug holiday” strategy should not be implemented for denosumab, estrogen, SERMs or teriparatide. Elsevier 2019-06-08 /pmc/articles/PMC6580330/ /pubmed/31431887 http://dx.doi.org/10.1016/j.crwh.2019.e00127 Text en © 2019 Published by Elsevier B.V. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Anagnostis, Panagiotis
Paschou, Stavroula A.
Kenanidis, Eustathios
Lambrinoudaki, Irene
Potoupnis, Michael
Tsiridis, Eleftherios
Goulis, Dimitrios G.
“Holidays” for osteoporosis drugs: A case-based approach
title “Holidays” for osteoporosis drugs: A case-based approach
title_full “Holidays” for osteoporosis drugs: A case-based approach
title_fullStr “Holidays” for osteoporosis drugs: A case-based approach
title_full_unstemmed “Holidays” for osteoporosis drugs: A case-based approach
title_short “Holidays” for osteoporosis drugs: A case-based approach
title_sort “holidays” for osteoporosis drugs: a case-based approach
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6580330/
https://www.ncbi.nlm.nih.gov/pubmed/31431887
http://dx.doi.org/10.1016/j.crwh.2019.e00127
work_keys_str_mv AT anagnostispanagiotis holidaysforosteoporosisdrugsacasebasedapproach
AT paschoustavroulaa holidaysforosteoporosisdrugsacasebasedapproach
AT kenanidiseustathios holidaysforosteoporosisdrugsacasebasedapproach
AT lambrinoudakiirene holidaysforosteoporosisdrugsacasebasedapproach
AT potoupnismichael holidaysforosteoporosisdrugsacasebasedapproach
AT tsiridiseleftherios holidaysforosteoporosisdrugsacasebasedapproach
AT goulisdimitriosg holidaysforosteoporosisdrugsacasebasedapproach

Ejemplares similares